Sharing knowledge to advance healthcare policies in Europe for people living with dementia and their carers: the ALCOVE project

Christine Barr1*, Nathalie Riolacci-Dhoyen1, Maggie Galbraith1, Armelle Leperre-Desplanques1 and the ALCOVE GROUP2

Abstract

Background: Alzheimer’s disease and other related dementias are public health priorities in the European Union due to their prevalence, cost and profound impact on society. Because of these pressing implications, the European Union decided to create a Joint Action to share knowledge about dementia and health policy in order to preserve the health, quality of life, autonomy and dignity of people living with dementia and their carers in Europe.

Methods: ALCOVE is a European Community-funded Joint Action coordinated by the HAS (French National Authority for Health) with a 24-month duration. The project’s life cycle has been divided into the following four steps: (1) collection of existing information, (2) analysis of existing information and making comparisons across Member States, (3) identifying Evidence, Needs, and Priorities, (4) drafting recommendations and disseminating them.

Results: 19 countries are participating in the ALCOVE initiative. The project will publish its final findings in 2013. The project’s objectives, participants, method, on-going procedures and work plans are already available on the ALCOVE website: http://www.alcove-project.eu/. Preliminary results show that recommendations will need to focus on clinical and epidemiological data collection, diagnostic system assessment, outstanding approaches for treating behavioural disorders, limiting antipsychotic use, and competence assessment in this vulnerable population.

Conclusions: The European Member States involved are mobilized to share best health policy practices in order to tackle the challenge of dementia’s threat on European health and social systems and to improve the quality of life and care for individuals and their family carers.

Keywords: Alzheimer’s disease and related dementia, Dementia, Public health, BPSD, Antipsychotics, Risk reduction, Prevalence, Diagnosis, Advanced declaration of will, Health care system

Background

The last 50 years in Europe have seen an overall dramatic increase in life expectancy, with a corresponding rise in the incidence of diseases linked to aging such as dementia [1,2]. More than 7 million Europeans are directly affected by dementia, the most common form being Alzheimer’s disease which is characterised by progressive memory loss and cognitive troubles as well as the occurrence of disturbing behaviour disorders [3,4]. Alzheimer’s disease and related dementias are public health priorities in EU Member States due to their prevalence, cost and profound impact on society [5-9].

ALCOVE is a European Community-funded Joint Action (JA) coordinated by the HAS (French National Authority for Health), with the participation of 19 European Member States (MS) and involving 30 partner organisations (Figure 1, Additional file 1: Annex 1). The
organisations have been designated by their national
governments for their clinical, epidemiological or public
health expertise in Alzheimer’s disease and related
dementias.

The project aims to share knowledge about dementia
and to preserve the health, quality of life, and the auton-
omy and dignity of people living with the disease and
their carers in European Union Member States. To this
end, the ALCOVE project aims to establish a sustainable
European network (1) to provide better care and services
all along the progression of Alzheimer’s disease and
related dementia from early diagnosis to home or insti-
tutionalized care, including reduction in the risk related
to the use of antipsychotics [10-13]; (2) to exchange
experiences and knowledge about dementia health policy
[13-15]; and (3) to inform and advise decision-makers,
healthcare professionals, carers, and citizens.

The goal of the ALCOVE-Joint Action is to reply to
the following strategic questions in order to guide public
health decisions in EU Member States by fostering better
coordination of the management of care for people
living with Alzheimer’s Disease (AD) and other related
dementias:

1. How to improve data for better knowledge about
dementia prevalence?

2. How to improve access to a dementia diagnosis and,
in the process, to the appropriate care as early as
possible?

3. How to improve care for people living with dementia
and particularly those exhibiting the Behavioural and
Psychological Symptoms of Dementia (BPSD)?

4. How to improve the rights of people with dementia
regarding advance declarations of will and
competence assessments?

The use of antipsychotics in this vulnerable population
has been chosen as a common ground for the 4 core
questions and as a guide to support the implementation
of good practices in the field of risk prevention asso-
ciated with the use of psychotropic drugs in people liv-
ing with dementia [12,13,16].
Methods

ALCOVE is an operational public health project with a 24-month duration. The project’s life cycle has been divided into four steps as described below. ALCOVE is currently working on steps 1 and 2 and has already begun collecting the existing information on available epidemiological data in Europe and on the most recent scientific findings regarding good practices in the care of individuals living with Alzheimer’s disease and related dementia. The project’s next steps will be to identify and prioritize the needs of people living with Alzheimer’s disease and related dementia and to issue recommendations on how to best address these needs. The process that ALCOVE is following is highlighted in Figure 2 [17].

1. Collection of existing information

ALCOVE’s method entails reviewing recent scientific literature, with an explicit strategy: period and terms of research, sources of information [Automated bibliographic databases; Medline (National Library of Medicine, United States), the Cochrane Library (Wiley Interscience, United States), OVID, In-Process & Other Non-Indexed Citations and Ovid MEDLINE; Pascal; CLEIRPPA database (FNG), French National Geriatrics; National Guideline Clearinghouse (United States); HTA Database (International Network of Agencies for Health Technology Assessment - INAHITA), Guidelines International Network]. Additionally, a grey literature search was conducted to identify Alzheimer Plans that have been implemented at the national level and evaluations of such plans. To this end, the project has consulted and used relevant websites, such as those of learned institutions specializing in the studied field, as well as the bibliographies of the selected articles and documents.

This literature review is being combined with the use of ALCOVE-designed questionnaires (Additional file 2: Annex 2) to collect relevant information from principal actors in the field such as National Health Ministries, Physicians, Geriatricians, and Memory Clinics as well as National Health Registries and databases.

2. Analysis of existing information and making comparisons across Member States

ALCOVE’s first aim is to improve data for better knowledge about dementia: the research is focused on prevalence rates for Alzheimer’s disease and related dementia in Europe and the evaluation of the rate of exposure of Europeans living with dementia to antipsychotics.
In an effort to understand differences across MS in the timely access to a dementia diagnosis, ALCOVE will compare national recommendations for a timely diagnosis in order to establish a common definition. ALCOVE will investigate the organisation of diagnostic systems within Member States and the localisation and availability of Memory Clinics while examining the role of General Practitioners and strategies for a timely diagnosis in Primary Care, including nursing/retirement homes. In order to improve care for people living with dementia, and particularly those experiencing behavioural disorders, ALCOVE will identify the existing support systems for those exhibiting BPSD, specifically focusing on innovative and/or efficient measures in limiting the prescription of antipsychotics to treat BPSD, which have recently been shown to be non-effective and deleterious for these patients [12,13].

ALCOVE will analyze the current education that health care personnel who work with patients exhibiting BPSD receive and highlight areas where this education could be enriched. Furthermore, ALCOVE will be collecting data on the procedures currently in place for the prescription of antipsychotics (the majority have an off-label use) in clinical practice within European countries. Within the context of ALCOVE’s fourth question regarding improving the autonomy of individuals living with Alzheimer’s disease and related dementia, the project will be identifying the existing national regulations on advance directives of will and informed consent, investigating the possibility of moving towards a more coordinated European perspective, describing how advance directives and informed consent are used in practice for people living with Alzheimer’s disease and related dementia, and identifying the good practices for competence assessment while documenting how the prescription of antipsychotic drugs could affect their validity.

3. Evidence, needs, and priorities
Based on the analyses and the answers to the four main questions, attained through the combination of literature searches, and the analyses of evidence and assessed practices or systems, ALCOVE will be able to both identify (a) the systems or practices devoted to dementia in place in the different European Union Member States, including how much they differ or vary from one another; and (b) the good practices and support systems which could be promoted at the European level.

4. Recommendations and Dissemination
Finally, ALCOVE will be making recommendations concerning good practices in epidemiological data collection, in the organisation of health systems or services for an earlier diagnosis, in the support systems and educational programmes for preventing BPSD and the overuse of antipsychotics, in competence assessment and the drafting of advanced declarations of will for this population.

Dissemination of our findings and analyses will be assured by a dedicated website, public and scientific conferences, professional publications and cooperation with other international referent networks.

Results and discussion
The ALCOVE JA is an on-going project that will not publish its findings until 2013. As such, it is not generating original research, but rather is analyzing recent scientific findings and current treatment and care realities in Europe so that recommendations can be generated for good practices in diagnosing and treating individuals living with Alzheimer’s disease and related dementia, both at a theoretical and scientific level. The project’s objectives, participants, method and on-going procedures and workplans are already available on the ALCOVE website: (http://www.alcove-project.eu/).

ALCOVE preliminary results show:

(1) That currently there is a discrepancy between the observed rate of prevalence in the national health systems, when this data is available, and the observed rate in cohorts. An updated mapping of different sources such as national insurance databases, registries, cohorts, surveys and recommendations to improve the quality and coherence of data collection could contribute to a better knowledge of the prevalence of Alzheimer’s disease and related dementia, which is crucial in the construction of relevant strategies. [5,6]

(2) That Alzheimer’s disease and related dementia are under-diagnosed all across European Union Member States. At this stage, improving diagnosis quality means making a timely diagnosis of the disease. Several European countries have already been working with memory centres for 10 years and the first appraisals of their effectiveness are now available. [18,19]

(3) That delivering better care in the treatment of BPSD is a shared and high level priority. BPSD is a large burden for daily carers and health professionals, so much so that it is a major reason behind early institutionalisation and/or the prescribing of antipsychotics. Currently, new non-pharmaceutical interventions are being implemented in an effort to reduce BPSD and their consequences, such as targeted care techniques and psychological...
and environmental interventions. The assessment of these non-pharmaceutical approaches is still ongoing. [14,20-24]

(4) Various and heterogeneous legal dispositions for people living with dementia are available in European Union Member States. An important question is how to find a better balance between preserving autonomy while legally protecting the individual (driving licence, will). Health professionals need dedicated information and training on good practices for competence assessment in people living with dementia. [25-31]

(5) ALCOVE’s participants have decided that a special focus will be made on the inappropriate use of antipsychotics to treat the BPSD of Alzheimer’s disease and related dementia as this is an urgent issue affecting patient safety and the quality of life of individuals living with dementia and their carers [12-14,16] As the culmination of the project, ALCOVE will provide information on the exposure of patients living with dementia to antipsychotics in Europe and an evaluation of the existing antipsychotics risk reduction strategies for people living with dementia.

An operational set of improvement tools and methods (information support, indicators, professional programmes, clinical guidelines, etc) based on the European benchmarking performed by ALCOVE will be proposed and will be available on ALCOVE website (http://www.alcove-project.eu/).

Conclusion

ALCOVE’s partners and work package leaders share the concrete goal of ensuring patient safety and quality of life for individuals living with Alzheimer’s disease and other dementias in Europe. An important element of this goal and the tie that binds the work being completed by all of those involved is a focus on reducing the overexposure to antipsychotic drugs among individuals living with dementia. In compiling the most recent research and evidence of good practices already implemented in the care of dementia, it is ALCOVE’s mission to share this information so that Europeans living with Alzheimer’s disease will have access to new care options from which they will benefit.

By promoting the best options in Alzheimer’s disease care and providing a toolbox of care options, ALCOVE will help European Member States reduce the risks involved in the use of antipsychotic medications to treat BPSD, promote alternative treatments, and alert and educate carers so that they will be better equipped and more supported when caring for individuals living with Alzheimer’s disease.

Endnote

ALzheimer COoperative Valuation in Europe.

Additional files

Additional file 1: Annex 1. European Union Joint Action ALCOVE (Alzheimer COoperative Valuation in Europe) partners.

Additional file 2: Annex 2. ALCOVE QUESTIONNAIRES.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CB, NRD, MG, and ALD were all involved in drafting the manuscript and the AG was involved in drafting the questionnaires, collecting, and analysing the data. All authors were involved in the critical revision of the manuscript. All authors read and approved the final manuscript.

Authors’ information

ALCOVE GROUP: Dr Armelle Lepere – Desplanquers, Dr Nathalie Riolacci – Dhoyen, Christine Barr, Maggie Galbraith, Haute Autorité de Santé, France; Tomás López-Pería Ordóñez, Carlos Segovia, Gloria Villar Acevedo, Instituto de Salud Carlos III, Spain; Pr Michal Novák, Pr Rostislav Skabranova, Martina Jerzovicková, Slovenska Akademia Vied – Neuroimmunologicky Ustav, Slovakia; Pr Nicola Vanacore, Pr Francesca Galeotti, Pr Angela Giusti, Pr Fiorentino Capozzoli, Istituto Superiore di Sanità, Italy; Dr Karim Saad, Regional Clinical Lead for Dementia, Coventry UK; Pr Dawson Brooker, Dr Simon Evans, Dr Jerry La Fontaine, University of Wroclaw, UK; Jerry Bird Department of Health, UK; Dr Helena Hosia-Randel, Pr Matti Mäkelä, Harriet Finne-Soveri, Paivi Topo, Ulla Boniemi-Sulkava, National Institute of Health and Welfare, Finland; Bénédicte Gombaut, Gerrit Raws, Tom Goffin, King Baudoin Foundation, Belgium; Dr Catherine Helmer, INSERM, France; Pr Anders Wilmo, Karolinska Institute, Sweden; Areli Ethymiou, Eleini Margioli, Nikolaou Costas, Maria Panagioutou, Paraskevi Salka, Athens Association of AD and Related Disorders, Greece; Teresa di Fiandara, Giovanni Nicoletti, Fabrizio Oleari, Fiammetta Landoni, Cecilia Precioso, Ministero della Salute, Italy; Barbara Borroni, Luca Rozzini, Enza Castronovo, Alessandro Padovani, University of Brescia, Neurology Clinic, Italy; Pr Wladimir Kuznecovs, Riga Centre of Psychiatry and Addiction Disorders, Latvia; Pr Daiva Raštyne, Kaunas University of Medicine, Lithuania; Pr Gemma Villanueva, Pr Gemma Lopez Argumendy, Fundacion Vasca de innovacion e investigación Sanitarias, Spain; Dr Gregory Emerly, Virgieh Ponelle, Pr Emmanuel Hirs, Espace Ethique de Assistance Publique des Hôpitaux de Paris, France; Irene K-Georgiou, Health Services, Ministry of Health, Cyprus; Martina Málová, Ceska alzheimerovska spolecnost, Czech Republic; Janos Kalman, University of Szeged - Szegedi Tudomanyegyetem, Hungary; Genovefa Paulauksiene, Ministry of Health, Lithuania; Valmantas Budrys, Vilnius University Faculty of Medicine, Lithuania; Dorothee Knauer-Hübkel, Ministère de la Santé, Luxembourg; Malou Kapgen, Ministère de la Famille et de l’intégration, Luxembourg; Isabelle Avallone, Ministéru tas-Sahha, l-Anġjani u l-Kura fil-Kommunita, Malta; Jacqueline Hoogendam, Ministry of Health, Welfare and Sports, Netherlands; Kristin Lakke, Ministry of Health and Care services, Norway; Miguel Xavier, National Coordinating Body for Mental Health, Portugal; Lubica Pitlova, Ministerstvo školstva Slovenskej Republiky, Bratislava, Slovakia; Isabel Saiz, Spanish Ministry of Health, Spain; Louise McCabe, Dementia Services Development Centre, University of Sterling, UK.

Acknowledgement

This presentation arises from the JOINT ACTION ALCOVE which has received funding from the European Union in the framework of the Public Health Programme (Grant Number 2010 22 01).

Author details

1Haute Autorité de Santé (HAS), Avenue du Stade de France, 93218, Saint-Denis La Plaine, France. 2ALzheimer COoperative Valuation in Europe Group, c/o Executive Agency for Health and Consumers, Health Unit, DRB A3/050, L-2920, Luxembourg, United Kingdom.
References

1. Leon DA: Trends in European life expectancy: a salutary view. International Journal of Epidemiology 2011, 40(3):715–717. doi:10.1093/ije/dyr031.

2. Health at a Glance 2011: OECD Indicators. http://www.oecd.org/els/healthbrain/43496288.pdf

3. Lobo A, Launer L, Fratiglioni L, Andersen K, Di Carlo A, Breter MM, Copenfal JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54(11 Suppl 5):S4–9.

4. Kiejna A, Frydecka D, Adamowski T, Bickel H, Reynish E, Prince M, Caracciolo S: Variations on the presentation of Alzheimer disease. J Multidiscip Healthc. 2011, 5:165. doi:10.3233/JAD-2010-091489.

5. Mathers C, Leonardi M: Global burden of dementia in the year 2000: summary of methods and data sources. Global Burden of Disease 2000.

6. Matias M: European Parliament resolution of 19 January 2011 on a European initiative on Alzheimer’s disease and related dementia. http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P7-TA-2011-0016+0+DOC+XML+V0//EN

7. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Martensson B, Pointon B, Tudose C, Holmrova I: Recommendations on end-of-life care for people with dementia. J Nutr Health Aging 2010, 14(2):136–9.

8. Luengo-Fernandez R, Leal J, Gray AJ: Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis 2011, 27(1):187–96.

9. Karlawish J: Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011, 77(15):487–93.

10. Grand JH, Caspar S, Macdonald SW: Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc. 2011, 4:125–47.

11. O’Neill ME, Freeman M, Christensen V, Telerant R, Addleman A, Kansagara D: A Systematic Evidence Review of Non-pharmacological Interventions for Behavioral Symptoms of Dementia [Internet]. Washington (DC): Department of Veterans Affairs; 2009.http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=dementiatreatment

12. Ballard CG, Waite J, Birks J: Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. http://onlineibrary.wiley.com/doi/10.1002/14651858.CD004334.pub2/abstract

13. Banerjee S: The use of antipsychotic medication for people with dementia: A time for action. An independent report commissioned and funded by the Department of Health (England). www.dh.gov.uk (Keyword Banneree) (Accessed January, 2010).

14. French Alzheimer Public Health Plan. http://www.plan-alzheimer.gouv.fr/-/44-measures.html

15. Alzheimer Europe. http://www.alzheimer-europe.org

16. Alert and mastering the antipsychotics’ iatrogenicity in Alzheimer Disease. http://www.has-sante.fr/portail/jcms/c_1055440/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics

17. Collaborative Method. http://www.has-sante.fr/portail/jcms/c_1099538/syntheses-methodologiques

18. Hausern L, Frölich L, Gardette V, Reynish E, Dusser PJ, et al: Regional Variation on the Presentation of Alzheimer’s Disease Patients in Memory Clinics within Europe: Data from the ICTUS study. Journal of Alzheimer’s Disease 2010, 155:155–165. doi:10.3233/JAD-2010-091489.

19. Ramakers I, Verhey F: Development of memory clinics in the Netherlands: 1998 to 2009. Aging & Mental Health 2011, 15(1):34–39.

20. Alzheimer’s disease and related conditions: Management of behavioural disorders 2009. http://www.has-sante.fr/portail/jcms/c_1055540/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics

21. Petrovic M, Hurt C, Collins D, Burns A, Czum V, et al: Clustering of behavioural and psychological symptoms in dementia (BPSD): A European Alzheimer’s dementia consortium (EADC) study. Acta Clin. Belg. 2007, 62:426–432.

22. Passmore MJ, Ho A, Gallagher R: Behavioural and psychological symptoms in moderate to severe Alzheimer’s disease: a palliative care approach

23. Van De Ven G, Draskovic I, Adang E, Art R, Post A, Zuidema S, et al: Improving person-centred care in nursing homes through dementia care mapping: design of a cluster randomised controlled trial. BMC Geriatrics 2012, 12:1. doi:10.1186/1471-2393-12-1

24. Alzheimer’s disease and related conditions: Health monitoring for family carers - quick reference guide 2010. [http://www.has-sante.fr/portail/jcms/c_1055540/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics]

25. Vermoolens-Dassen M, Draskovic I, McCleery J, Down M: Cognitive reframing for carers of people with dementia. Cochrane Database of Systematic Reviews 2011, doi:10.1002/14651858.CD005318.pub2. Issue 11. Art. No.: CD005318

26. Dementia in Europe Yearbook 2011. www.AlzheimerEurope.org

27. Howe EG: Ethical challenges when patients have dementia. J Clin Ethics 2011, 22(3):203–11.

28. de Boer ME, Hertogh CM, Dräes RM, Jonker C, Eefsting JA: Advance directives in dementia: issues of validity and effectiveness. Int Psychogeriatr 2010, 22:201–8. Epub 2009 Aug 10.

29. European Dementia Consensus Network: Competence Assessment in Dementia. 2008. Ed. Stopppe.

30. Gove D, Sparr S, Dos Santos Bernardo AM, Cosgrave MP, Jansen S, Martensson B, Pointon B, Tudose C, Holmrova I: Recommendations on end-of-life care for people with dementia. J Nutr Health Aging 2010, 14(2):136–9.

31. Wortmann M, Andreiu S, Mackell J, Knox S: Evolving attitudes to Alzheimer’s disease and related dementia among the general public and caregivers in Europe: findings from the IMPACT survey. J Nutr Health Aging 2010, 14(7):351–4.